Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

This study has been completed.

Study NCT00088894 Information provided by Cancer and Leukemia Group B

First Received: August 4, 2004 Last Updated: March 1, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	June 2010
Primary Completion Date:	June 2006 (Final data collection date for primary outcome measure)

Publications:

Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010 Jul 6; [Epub ahead of print]

Innocenti F, Owzar K, Cox N, et al.: Heritable interleukin-17F (IL17F) gene variation and overall survival (OS) in pancreatic cancer patients (pts): results from a genome-wide association study (GWAS) in CALGB 80303. [Abstract] J Clin Oncol 27 (Suppl 15): A-4531, 2009.

Kindler HL, Niedzwiecki D, Hollis D, et al.: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. [Abstract] American Society of Clinical Oncology 2007 Gastrointestinal Cancers Symposium, 19 -21 January 2007, Orlando, Florida A-108, 2007.

Romanus D, Archer L, Wang X, et al.: Does health-related quality of life (HRQL) improve for patients who respond to chemotherapy? Analysis of patients with advanced pancreas cancer (APC) receiving gemcitabine on Cancer and Leukemia Group B (CALGB) study #80303. [Abstract] J Clin Oncol 25 (Suppl 18): A-9008, 495s, 2007.

Schrag D, Archer L, Wang X, et al.: A patterns-of-care study of post-progression treatment (Rx) among patients (pts) with advanced pancreas cancer (APC) after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study #80303. [Abstract] J Clin Oncol 25 (Suppl 18): A-4524, 2007.